Clinical status, quality of life, and work productivity in Crohns disease patients after one year of treatment with adalimumab
Rev. esp. enferm. dig
; 109(2): 122-129, feb. 2017. tab, graf
Article
en En
| IBECS
| ID: ibc-159855
Biblioteca responsable:
ES1.1
Ubicación: BNCS
ABSTRACT
Objective:
Clinical trials have shown the efficacy of adalimumab in Crohns disease, but the outcome in regular practice remains unknown. The aim of the study was to examine clinical status, quality of life, and work productivity of Crohns disease patients receiving adalimumab for one year in the context of usual clinical practice. Material andmethods:
This was a prospective, observational study with a one-year follow-up. After baseline, Crohns disease patients were evaluated at 1, 3, 6, 9, and 12 months after starting treatment with adalimumab. Outcome variables included clinical status (measured with CDAI), quality of life (measured with EuroQoL-5D and IBDQ), and work productivity (measured with WPAI questionnaire). These outcome variables were compared using the Students t test or Wilcoxon test for paired comparison data according to the data distribution. Statistical significance was set at two-sided p < 0.05.Results:
The sample was composed of 126 patients (age [mean] 39.1 ± [standard deviation] 13.8 years; 51% male). Significant changes were observed during the follow-up period CDAI decreased from [median] 194 ([25-75 percentiles] 121-269) to 48.2 (10.1-122.0) (p < 0.05); the EuroQoL-5D increased from 0.735 (0.633-0.790) to 0.797 (0.726-1.000) (p < 0.05); the EuroQoL- 5D visual analogue scale increased from 50.0 (40-70) to 80.0 (60- 90); (p < 0.05) and the IBDQ increased from 56.7 (51.6-61.5) to 67.5 (60.1-73.6) (p < 0.05). The total work productivity impact decreased from 53% to 24% (p < 0.05).Conclusions:
In regular practice, adalimumab is clinically effective in the treatment of Crohns disease patients and results in a significant improvement in quality of life and work product (AU)RESUMEN
No disponible
Texto completo:
1
Bases de datos:
IBECS
Asunto principal:
Calidad de Vida
/
Enfermedad de Crohn
/
Impacto Psicosocial
/
Relación Dosis-Respuesta a Droga
Tipo de estudio:
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Adult
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Rev. esp. enferm. dig
Año:
2017
Tipo del documento:
Article